Still Hungry on Wegovy 0.25mg — Is That Normal?

Why does the 0.25mg dose seem to do so little for appetite?

Wegovy (semaglutide) works by activating GLP-1 receptors in the brain and gut, gradually reducing appetite signals and slowing the rate at which the stomach empties. At 0.25mg, that activation is gentle by design. The licensed titration schedule (0.25mg for the first four weeks, rising through 0.5mg, 1.0mg, 1.7mg and eventually to the 2.4mg maintenance dose) is structured the way it is because going straight to a higher dose greatly increases the risk of nausea, vomiting and other gastrointestinal discomfort.

So the starter dose is essentially a calibration phase. Your system is meeting a new medicine, and the priority is tolerance, not transformation. Most people who are still hungry on Wegovy 0.25mg are experiencing exactly what the clinical team expects. The STEP 1 trial (which produced the headline trial results for semaglutide 2.4mg) tested the medicine at maintenance dose after a full titration period, not at 0.25mg. Results at the starting dose were never the point.

The NHS semaglutide medicines page confirms that the dose is increased gradually to reduce the chance of side effects, and that the therapeutic effect builds over time. If you want a broader picture of where 0.25mg sits within the full schedule, the Wegovy dose guide walks through each step.

Is it possible to feel no different at 0.25mg and still lose weight later?

Yes, and it is more common than many people expect. Appetite suppression with semaglutide tends to become more noticeable from around the 1.0mg or 1.7mg mark, when the dose is genuinely therapeutic. At 0.25mg, some people feel slightly fuller than usual; many feel no different at all. Neither response predicts how you will respond at higher doses.

There is a practical parallel worth noting: many patients who report that Wegovy 0.25mg still leaves them hungry also describe little nausea at this phase, which is a reasonable trade-off. The side-effect profile and the appetite effect often travel together, as the dose increases, both tend to become more pronounced before settling. Keeping your injection routine consistent helps. Storing your pen correctly (upright in the fridge door, not crammed at the back where temperatures can dip unevenly) matters more than it might seem, because semaglutide is temperature-sensitive and a damaged pen delivers less reliably.

If you are curious what research shows at the full maintenance dose, the evidence on weight loss at 2.4mg is covered separately in our overview of weight loss on Wegovy 2.4mg. It is a useful reference point for where the journey is heading.

Should you ask your prescriber to speed up the titration?

It is reasonable to raise the question, but the answer is almost always to stay the course. The titration schedule is not arbitrary. Moving to a higher dose early increases the probability of GI side effects severe enough to make people stop treatment altogether, which would be counterproductive. The schedule is a considered clinical decision built into the licensed prescribing framework.

That said, your prescriber should know how you are feeling. If the hunger is making the plan feel unmanageable, or if you are compensating in ways that worry you, those conversations matter. A prescriber can also help you think through whether you are eating patterns that work with reduced-appetite treatment (protein adequacy, fibre, hydration) even before the appetite suppression kicks in more strongly.

Our frequently asked questions cover several related practical concerns, and the Wegovy overview page has a fuller picture of how treatment works from start to finish. For context on what hunger can look like further along in treatment, hunger at the 1.7mg dose is a different experience that is also worth reading ahead of that phase.

When does hunger on Wegovy actually become something to flag?

Persistent hunger throughout titration, right up to the maintenance dose, is worth discussing with your prescriber, it can occasionally point to factors like how the injection is being administered, storage conditions, or whether another health consideration is affecting response. Wegovy is a prescription medicine, and follow-up reviews exist precisely for these situations.

Separately, if hunger is accompanied by symptoms that feel more medical (dizziness, nausea that does not settle, severe stomach pain) contact your prescriber or GP promptly. The NHS page for semaglutide lists the side effects that warrant medical advice, including the signs of pancreatitis (severe, persistent abdominal pain that may radiate to the back) which should prompt urgent care. You can also report any unexpected side effects through the MHRA Yellow Card scheme.

For those further into treatment who are still finding hunger difficult, the experience at higher doses is explored in more detail at still hungry on Wegovy 2.4mg and hunger on Wegovy 2.4mg, both of which address a clinically different situation from the 0.25mg phase. Wegovy treatment costs and what private prescribing involves are set out on the Wegovy price comparison page if that context is useful.